

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Original) Crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl) cyclopropane acetic acid having characteristic X-ray powder diffraction peaks, designated by 2θ and expressed in degrees, at $6.5\pm 0.2^\circ$, $10.0\pm 0.2^\circ$, $15.5\pm 0.2^\circ$, $18.3\pm 0.2^\circ$, $20.4\pm 0.2^\circ$ and $24.6\pm 0.2^\circ$.

2. (Currently amended) The crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-cyclopropane acetic acid according to claim 1, characterized by a monoclinic space group $[[P\ 2_1]]$ $P\ 2_1$ and by displaying unit cell parameters comprising: crystal axis lengths of $a = 7.95\pm 0.02\ \text{\AA}$, $b = 21.94\pm 0.02\ \text{\AA}$, $c = 17.95\pm 0.02\ \text{\AA}$ and an angle between the crystal axes of $\beta = 100.03\pm 0.02^\circ$.

3. (Currently amended) The crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-cyclopropane acetic acid according to claim 1, characterized in that it is provided with a purity of greater than 90.0%[[,]] ~~preferably greater than 95%, preferably greater than 99%, preferably greater than 99.9%.~~

4. (Currently amended) A process for preparing the crystalline ~~1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)-propyl)thio)methyl)cyclopropane~~ 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-

phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)-propyl)thio)methyl)cyclopropane acetic acid according to claim 1, comprising the steps

-dissolving a salt of 1-(((1(R)-3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid in a solution A comprising at least one organic solvent,

-converting the salt of 1-(((1(R)-3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid into acid,

-crystallizing the 1-(((1(R)-3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio) methyl)cyclopropane acetic acid, and

-optionally isolating the crystalline 1-(((1(R)-3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)-cyclopropane acetic acid.

5. (Original) The process according to claim 4, characterized in that the converting step is carried out with a solution B comprising at least one aqueous solution and a chromatographic column, respectively.

6. (Currently amended) The process according to claim 5, characterized in that the dissolving step and converting step are carried out together in a mixture comprising solution A and solution B[[,]] ~~preferably in a ratio solution B : solution A of 1:10 to 10:1.~~

7. (Currently amended) [[A]] The process according to claim 5, characterized in that the 1-(((1(R)-3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-

hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid is eluted from the column with the solution A comprising at least one organic solvent.

8. (Currently amended) Amorphous form I of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)-cyclopropane acetic acid having a characteristic DSC thermogram with two endothermic peaks, one at between 43°C and 53°C[[,]] ~~preferably between 47°C and 49°C, preferably at 48°C~~ and one at between 143°C and 153°C, ~~preferably between 147°C and 149°C, preferably at 148°C~~ and further having one exothermic peak at between 86°C and 96°C[[,]] ~~preferably between 90°C and 92°C, preferably at 91°C.~~

9. (Original) A process for preparing the amorphous form I of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 8, comprising grinding the crystal form of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid.

10. (Original) Amorphous form II of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)-cyclopropane acetic acid having a characteristic DSC thermogram as shown in Fig. 9.

11. (Original) The process for preparing the amorphous form II of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 10, comprising

-providing a suspension of the crystal form of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)-cyclopropane acetic acid, or a salt thereof, in an acidic aqueous solution and

-isolating said amorphous form II.

12. (Previously presented) A pharmaceutical composition comprising the crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to claim 1, and one or more pharmaceutically acceptable carriers or excipients

13. (Currently amended) A method of treating asthma in a human, comprising administering to a human in need thereof Crystalline crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)-thio)methyl) cyclopropane acetic acid according to claim 1[[,]] ~~for the use of treating asthma in a human.~~

14. (Currently amended) A pharmaceutical composition, comprising the ~~crystalline~~ amorphous form I of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to ~~the amorphous form I of~~ claim 8, and one or more pharmaceutically acceptable carriers or excipients.

15. (Currently amended) A pharmaceutical composition, comprising the ~~crystalline~~ amorphous form II of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic

acid according to ~~the amorphous form II~~ of claim 10, and one or more pharmaceutically acceptable carriers or excipients.

16. (Currently amended) A method of treating asthma in a human, comprising administering to the human in need thereof the amorphous form I of Crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)-propyl)thio)methyl)cyclopropane acetic acid according to the amorphous form I of claim 8, for the use of treating asthma in a human.

17. (Currently amended) A method of treating asthma in a human, comprising administering to the human in need thereof the amorphous form II of Crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to the amorphous form II of claim 10, for the use of treating asthma in a human.

18. (New) The crystalline 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid according to claim 3, having a purity of greater than 95%, greater than 99%, or greater than 99.9%.

19. (New) The process according to claim 6, wherein the ratio of solution B : solution A is from 1:10 to 10:1.

20. (New) The amorphous form I of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)-cyclopropane acetic acid according to claim 8, having a characteristic DSC thermogram

with two endothermic peaks, one at between 47°C and 49°C or at 48°C and one between 147°C and 149°C or at 148°C, and further having one exothermic peak at between 90°C and 92°C or at 91°C.